VDG Pharma SRL
VDG Pharma reported total assets of 644,872 € at the end of the 2025 financial year (annual accounts filed with the NBB on 27 May 2026).
The score of VDG Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +81 % Total assets -6 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
VDG Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 42,205 € | ||||
| Equity | 295,767 € | ||||
| Cash | 1,812 € | ||||
| EBITDA | 79,283 € | ||||
| Total assets | 644,872 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 May 2026
- Year ended 31 Dec 2024filed on 17 Jul 2025
- Year ended 31 Dec 2023filed on 03 Jun 2024
- Year ended 31 Dec 2022filed on 30 May 2023
- Year ended 31 Dec 2021filed on 30 May 2022
VDG Pharma's financial analysis
- Solvency45.9%sector median: 53.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of VDG Pharma
VDG Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0728.788.615
- VAT number
- BE0728788615
- Peppol
- Registered · 0208:0728788615 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 24 Jun 2019
- Registered office
- 2100 Antwerp
- Latest accounts
- 2025 · filed on 27 May 2026
- Activity
- Activities of head offices (NACE 70100)
VDG Pharma (SRL) has been based in Antwerp since 2019, active in: activities of head offices. For 2025, it reports a net profit of 42,205 € and equity of 295,767 €; its revenue is not published. Its solvency stands at 45.9%, below the median of its sector (53.1%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to VDG Pharma
Companies in the same business, of comparable size and area, outside its group.
- Lagraph Activities of head offices Oosterzele · balance sheet 662,087 €
- Sic Parvis Magna Activities of head offices Aartselaar · balance sheet 625,902 €
- Barro Invest Activities of head offices Ledegem · balance sheet 565,796 €
- CCT4Green Activities of head offices Grimbergen · balance sheet 768,297 €
- Ultimo Groep Activities of head offices Hamont-Achel · balance sheet 524,862 €
- Scale-Up Invest Activities of head offices Liège · balance sheet 816,923 €
- Zilina Activities of head offices Poperinge · balance sheet 490,939 €
- Schellekens Holding Activities of head offices Beveren-Kruibeke-Zwijndrecht · balance sheet 887,894 €
Frequently asked questions about VDG Pharma
What is the revenue of VDG Pharma?
VDG Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of VDG Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0728788615 for VDG Pharma, if the company is VAT-registered. Its company number (CBE) is 0728.788.615.
Where is the registered office of VDG Pharma?
According to the CBE register, the registered office of VDG Pharma is in 2100 Antwerp.
What is the equity of VDG Pharma?
At the close of the 2025 financial year, the equity of VDG Pharma amounts to 295,767 €, a solvency of 45.9% of total assets.
Who manages VDG Pharma?
The register lists 2 active mandates at VDG Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of VDG Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →